This database contains 68 studies, archived under the term: "Canada"
Click here to filter this large number of results.
Elder-Clowning in Long-Term Dementia Care: Results of a Pilot Study
Kontos, Pia,
Miller, Karen-Lee,
Colobong, Romeo,
Palma Lazgare, Luis I.,
Binns, Malcolm,
Low, Lee-Fay,
Surr, Claire,
Naglie, Gary
OBJECTIVES: To assess the effects of elder-clowning on moderate to severe behavioral and psychological symptoms of dementia (BPSD) in nursing home residents with dementia, primarily of the Alzheimer’s type. DESIGN: Before-and-after study. SETTING: Nursing home. PARTICIPANTS: Nursing home residents with moderate to severe BPSD, as defined according to a Neuropsychiatric Inventory-Nursing Home version (NPI-NH) score […]
The effects of oxytocin on social cognition and behaviour in frontotemporal dementia
Jesso, S.,
Morlog, D.,
Ross, S.,
Pell, M. D.,
Pasternak, S. H.,
Mitchell, D. G. V.,
Kertesz, A.,
Finger, E. C.
Patients with behavioural variant frontotemporal dementia demonstrate abnormalities in behaviour and social cognition, including deficits in emotion recognition. Recent studies suggest that the neuropeptide oxytocin is an important mediator of social behaviour, enhancing prosocial behaviours and some aspects of emotion recognition across species. The objective of this study was to assess the effects of a […]
Efficacy of a cognitive training programme for mild cognitive impairment: Results of a randomised controlled study
Jean, Léonie,
Simard, Martine,
Wiederkehr, Sandra,
Bergeron, Marie-Ève,
Turgeon, Yves,
Hudon, Carol,
Tremblay, Isabelle,
van Reekum, Robert
This study aimed to determine the efficacy of cognitive training in a 10-week randomised controlled study involving 22 individuals presenting with mild cognitive impairment of the amnestic type (MCI-A). Participants in the experimental group (n = 11) learned face–name associations using a paradigm combining errorless (EL) learning and spaced retrieval (SR) whereas participants in the […]
Electronic organiser and Alzheimer’s disease: fact or fiction?
Imbeault, Hélène,
Bier, Nathalie,
Pigot, Hélène,
Gagnon, Lise,
Marcotte, Nicolas,
Fulop, Tamas,
Giroux, Sylvain
Alzheimer’s disease is a degenerative disease characterised by a progressive loss of cognitive functions and impairment of activities of daily living severe enough to interfere with normal functioning. To help persons with this disease perform a variety of activities, our research team developed AP@LZ, an electronic organiser specifically designed for them. Two participants with Alzheimer’s […]
Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: A phase 2, randomised, double-blind, placebo-controlled trial
Background: PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington’s disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington’s disease. Methods: In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥ 25 years old) […]
Object alternation: a novel probe of medial frontal function in frontotemporal dementia
Freedman, Morris,
Binns, Malcolm A.,
Black, Sandra E.,
Levine, Brian,
Miller, Bruce L.,
Ramirez, Joel,
Szilagyi, Gregory M.,
Scott, Christopher J. M.,
McNeely, Alicia A.,
Stuss, Donald T.
We studied behavioral variant frontotemporal dementia (bvFTD) using object alternation (OA) as a novel probe of cognition. This task was adopted from animal models and is sensitive to ventrolateral-orbitofrontal and medial frontal function in humans. OA was administered to bvFTD patients, normal controls, and a dementia control group with Alzheimer disease (AD). Two other frontal […]
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C.,
MacKinley, J.,
Blair, M.,
Oliver, L. D.,
Jesso, S.,
Tartaglia, M. C.,
Borrie, M.,
Wells, J.,
Dziobek, I.,
Pasternak, S.,
Mitchell, D. G. V.,
Rankin, K.,
Kertesz, A.,
Boxer, A.
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]